Guillaume Dorothée

Guillaume Dorothée

Auto-generated profile, based on publicly available information

Guillaume Dorothée

Sorbonne Université, Inserm, Centre de Recherche Saint-Antoine, CRSA, Immune System and Neuroinflammation Laboratory, Hôpital Saint-Antoine, Paris, France

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 December 2024 in Nature Reviews Immunology
Verified
Journal Article
Closed access
PDF file
MHMichael Thomas Heneka
Michael Thomas Heneka
WFWiesje M. van der Flier
Wiesje M. van der Flier
FJFrank Jessen
Frank Jessen
JHJeroen Hoozemanns
Jeroen Hoozemanns
DTDietmar Rudolf Thal
Dietmar Rudolf Thal
SRSean-Patrick Riechers
Sean-Patrick Riechers

15 March 2016 in Brain
Verified
Journal Article
Open access
PDF file
LHLorraine Hamelin
Lorraine Hamelin
JLJulien Lagarde
Julien Lagarde
GDGuillaume Dorothée
Guillaume Dorothée
CLClaire Leroy
Claire Leroy
MLMickael Labit
Mickael Labit
TTthe Clinical IMABio3 team
the Clinical IMABio3 team
While emerging evidence suggests that neuroinflammation plays a crucial role in Alzheimer’s disease, the impact of the microglia response in Alzheimer’s disease remains a matter of debate. We aimed to study microglial activation in early Alzheimer’s disease and its impact on clinical progression using a second-generation 18-kDa translocator protein positron emission tomography radiotracer together with amyloid imaging using Pittsburgh compound B positron emission tomography. We enrolled 96 subjects, 64 patients with Alzheimer’s disease and 32 controls, from the IMABio3 study, who had both 11C-Pittsburgh compound B and 18F-DPA-714 positron emission tomography imaging. Patients with Alzheimer’s disease were classified as prodromal Alzheimer’s disease (n = 38) and Alzheimer’s disease dementia (n = 26). Translocator protein-binding was measured using a simple ratio method with cerebellar grey matter as reference tissue, taking into account regional atrophy. Images were analysed at the regional (volume of interest) and at the voxel level. Translocator protein genotyping allowed the classification of all subjects in high, mixed and low affinity binders. Thirty high+mixed affinity binders patients with Alzheimer’s disease were dichotomized into slow decliners (n =10) or fast decliners (n =20) after 2 years of follow-up. All patients with Alzheimer’s disease had an amyloid positive Pittsburgh compound B positron emission tomography. Among controls, eight had positive amyloid scans (n = 6 high+mixed affinity binders), defined as amyloidosis controls, and were analysed separately. By both volumes of interest and voxel-wise comparison, 18-kDa translocator protein-binding was higher in high affinity binders, mixed affinity binders and high+mixed affinity binders Alzheimer’s disease groups compared to controls, especially at the prodromal stage, involving the temporo-parietal cortex. Translocator protein-binding was positively correlated with Mini-Mental State Examination scores and grey matter volume, as well as with Pittsburgh compound B binding. Amyloidosis controls displayed higher translocator protein-binding than controls, especially in the frontal cortex. We found higher translocator protein-binding in slow decliners than fast decliners, with no difference in Pittsburgh compound B binding. Microglial activation appears at the prodromal and possibly at the preclinical stage of Alzheimer’s disease, and seems to play a protective role in the clinical progression of the disease at these early stages. The extent of microglial activation appears to differ between patients, and could explain the overlap in translocator protein binding values between patients with Alzheimer’s disease and amyloidosis controls.

14 September 2021 in Nature Reviews Neurology
Verified
Journal Article
Closed access
PDF file
BBBrianne M. Bettcher
Brianne M. Bettcher
MTMalú G. Tansey
Malú G. Tansey
GDGuillaume Dorothée
Guillaume Dorothée
MHMichael T. Heneka
Michael T. Heneka

1 February 2016 in Brain
Verified
Journal Article
Closed access
PDF file
CDCira Dansokho
Cira Dansokho
DADylla Ait Ahmed
Dylla Ait Ahmed
SASaba Aid
Saba Aid
CTCécile Toly-Ndour
Cécile Toly-Ndour
TCThomas Chaigneau
Thomas Chaigneau
GDGuillaume Dorothée
Guillaume Dorothée
Recent studies highlight the implication of innate and adaptive immunity in the pathophysiology of Alzheimer’s disease, and foster immunotherapy as a promising strategy for its treatment. Vaccines targeting amyloid-β peptide provided encouraging results in mouse models, but severe side effects attributed to T cell responses in the first clinical trial AN1792 underlined the need for better understanding adaptive immunity in Alzheimer’s disease. We previously showed that regulatory T cells critically control amyloid-β-specific CD4+ T cell responses in both physiological and pathological settings. Here, we analysed the impact of regulatory T cells on spontaneous disease progression in a murine model of Alzheimer’s disease. Early transient depletion of regulatory T cells accelerated the onset of cognitive deficits in APPPS1 mice, without altering amyloid-β deposition. Earlier cognitive impairment correlated with reduced recruitment of microglia towards amyloid deposits and altered disease-related gene expression profile. Conversely, amplification of regulatory T cells through peripheral low-dose IL-2 treatment increased numbers of plaque-associated microglia, and restored cognitive functions in APPPS1 mice. These data suggest that regulatory T cells play a beneficial role in the pathophysiology of Alzheimer’s disease, by slowing disease progression and modulating microglial response to amyloid-β deposition. Our study highlights the therapeutic potential of repurposed IL-2 for innovative immunotherapy based on modulation of regulatory T cells in Alzheimer’s disease.

5 March 2022 in Molecular Neurodegeneration
Verified
Journal Article
Open access
PDF file
DBDiane Bairamian
Diane Bairamian
SSSha Sha
Sha Sha
NRNathalie Rolhion
Nathalie Rolhion
HSHarry Sokol
Harry Sokol
GDGuillaume Dorothée
Guillaume Dorothée
Slavica KranticSlavica Krantic
Slavica Krantic
Background: The implication of gut microbiota in the control of brain functions in health and disease is a novel, currently emerging concept. Accumulating data suggest that the gut microbiota exert its action at least in part by modulating neuroinflammation. Given the link between neuroinflammatory changes and neuronal activity, it is plausible that gut microbiota may affect neuronal functions indirectly by impacting microglia, a key player in neuroinflammation. Indeed, increasing evidence suggests that interplay between microglia and synaptic dysfunction may involve microbiota, among other factors. In addition to these indirect microglia-dependent actions of microbiota on neuronal activity, it has been recently recognized that microbiota could also affect neuronal activity directly by stimulation of the vagus nerve. Main messages: The putative mechanisms of the indirect and direct impact of microbiota on neuronal activity are discussed by focusing on Alzheimer’s disease, one of the most studied neurodegenerative disorders and the prime cause of dementia worldwide. More specifically, the mechanisms of microbiota-mediated microglial alterations are discussed in the context of the peripheral and central inflammation cross-talk. Next, we highlight the role of microbiota in the regulation of humoral mediators of peripheral immunity and their impact on vagus nerve stimulation. Finally, we address whether and how microbiota perturbations could affect synaptic neurotransmission and downstream cognitive dysfunction. Conclusions: There is strong increasing evidence supporting a role for the gut microbiome in the pathogenesis of Alzheimer’s disease, including effects on synaptic dysfunction and neuroinflammation, which contribute to cognitive decline. Putative early intervention strategies based on microbiota modulation appear therapeutically promising for Alzheimer’s disease but still require further investigation.

5 November 2016 in Brain
Verified
Journal Article
Open access
PDF file
CLCyril Laurent
Cyril Laurent
GDGuillaume Dorothée
Guillaume Dorothée
SHStéphane Hunot
Stéphane Hunot
EMElodie Martin
Elodie Martin
YMYann Monnet
Yann Monnet
DBDavid Blum
David Blum
Alzheimer’s disease is characterized by the combined presence of amyloid plaques and tau pathology, the latter being correlated with the progression of clinical symptoms. Neuroinflammatory changes are thought to be major contributors to Alzheimer’s disease pathophysiology, even if their precise role still remains largely debated. Notably, to what extent immune responses contribute to cognitive impairments promoted by tau pathology remains poorly understood. To address this question, we took advantage of the THY-Tau22 mouse model that progressively develops hippocampal tau pathology paralleling cognitive deficits and reappraised the interrelationship between tau pathology and brain immune responses. In addition to conventional astroglial and microglial responses, we identified a CD8-positive T cell infiltration in the hippocampus of tau transgenic mice associated with an early chemokine response, notably involving CCL3. Interestingly, CD8-positive lymphocyte infiltration was also observed in the cortex of patients exhibiting frontemporal dementia with P301L tau mutation. To gain insights into the functional involvement of T cell infiltration in the pathophysiological development of tauopathy in THY-Tau22 mice, we chronically depleted T cells using anti-CD3 antibody. Such anti-CD3 treatment prevented hippocampal T cell infiltration in tau transgenic animals and reverted spatial memory deficits, in absence of tau pathology modulation. Altogether, these data support an instrumental role of hippocampal T cell infiltration in tau-driven pathophysiology and cognitive impairments in Alzheimer’s disease and other tauopathies.